Outcome of hyperleukocytic adult acute myeloid leukaemia: A single-center retrospective study and review of literature

Leukemia Research

Volumn 32, Issue 8, 2008, Pages 1221-1227

  Marbello, Laura ^a   Ricci, Francesca ^a   Nosari, Anna Maria ^a   Turrini, Mauro ^a   Nador, Guido ^a   Nichelatti, Michele ^a   Tedeschi, Alessandra ^a   Vismara, Eleonora ^a   Morra, Enrica ^a  

^a OSPEDALE NIGUARDA CA GRANDA   (Italy)

Author keywords

Acute myeloid leukaemia; Leukapheresis; Leukocytosis; Leukostasis; Prognostic factor

Indexed keywords

CYTARABINE; ETOPOSIDE; FLUDARABINE; IDARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BRAIN HEMORRHAGE; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; GENETIC ANALYSIS; HUMAN; LEUKOCYTE COUNT; LEUKOSTASIS; LUNG INSUFFICIENCY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTE COUNT; LEUKOCYTOSIS; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS;

EID: 43049156573     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2008.01.004     Document Type: Article

References (30)

1. Dutcher J.P., Schiffer C.A., and Wiernik P.H. Hyperleukocytosis in adult acute nonlymphocytic leukemia: impact on remission rate and duration, and survival. J Clin Oncol 5 (1987) 1364-1372
2. Greenwood M.J., Seftel M.D., Richardson C., Barbaric D., Barnett M.J., Bruyere H., et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukaemia. Leuk Lymphoma 47 (2006) 1245-1252
3. Grimwade D., Walker H., Harrison G., Oliver F., Chatters S., Harrison C.J., et al., Medical Research Council Adult Leukemia Working Party. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. Blood 92 (1998) 2322-2333
4. Cheson B.D., Bennett J.M., Kopecky K.J., Büchner T., Willman C.L., Estey E.H., et al., International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia. Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukaemia. J Clin Oncol 21 (2003) 4642-4649
5. Appelbaum F.R., and Kopecky K.J. Long-term survival after chemotherapy for acute myeloid leukaemia. Cancer Suppl 80 (1997) 2199-2204
6. Bloomfield C.D., Lawrence D., Byrd J.C., Carroll A., Pettenati M.J., Tantravahi R., et al. Frequency of prolonged remission duration after high-dose cytarabine intensification in acute myeloid leukaemia varies by cytogenetic subtype. Cancer Res 58 (1998) 4173-4179
7. Anderson J.E., Kopecky K.J., Willman C.L., Head D., O'Donnell M.R., Luthardt F.W., et al. Outcome after induction chemotherapy for older patients with acute myeloid leukaemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study. Blood 100 (2002) 3869-3876
8. Chen C.C., Yang C.F., Yang M.H., Lee K.D., Kwang W.K., You J.Y., et al. Pretreatment prognostic factors and treatment outcome in elderly patients with de novo acute myeloid leukaemia. Ann Oncol 16 (2005) 1366-1373
9. Gupta V., Chun K., Yi Q.L., Minden M., Schuh A., Wells R., et al. Disease biology rather than age is the most important determinant of survival of patients ≥60 years with acute myeloid leukaemia treated with uniform intensive therapy. Cancer 103 (2005) 2082-2090
10. Flasshove M., Meusers P., Schütte J., Noppeney R., Beelen D.W., Sohrab S., et al. Long-term survival after induction therapy with idarubicin and cytosine arabinoside for de novo acute myeloid leukaemia. Ann Hematol 79 (2000) 533-542
11. Wahlin A., Markevarn B., Golovleva I., and Nilsson M. Improved outcome in adult acute myeloid leucemia is almost entirely restricted to young patients and associated with stem cell transplantation. Eur J Haematol 68 (2002) 54-63
12. Behringer B., Pitako J.A., Kunzmann R., Schmoor C., Behringer D., Mertelsmann R., et al. Prognosis of older patients with acute myeloid leukemia receiving either induction or noncurative treatment: a single-center retrospective study. Ann Hematol 82 (2003) 381-389
13. Visani G., Bernasconi P., Boni M., Castoldi G.L., Ciolli S., Clavio M., et al. The prognostic value of cytogenetics is reinforced by the kind of induction/consolidation therapy in influencing the outcome of acute myeloid leucemia-analysis of 848 patients. Leukemia 15 (2001) 903-909
14. Lichtman M.A., and Rowe J.M. Hyperleukocytic leukemias: rheological, clinical, and therapeutic considerations. Blood 60 (1982) 279-283
15. Myers T.J., Cole S.R., Klatsky A.U., and Hild D.H. Respiratory failure due to pulmonary leukostasis following chemotherapy of acute nonlymphocytic leukaemia. Cancer 51 (1983) 1808-1813
16. Soares F.A., Landell G.A., and Cardoso M.C. Pulmonay leukostasis without hyperleukocytosis: a clinicopathologic study of 16 cases. Am J Hematol 40 (1992) 28-32
17. Stucki A., Rivier A.S., Gikic M., Monai N., Schapira M., and Spertini O. Endothelial cell activation by myeloblasts: molecular mechanisms of leukostasis and leukemic cell dissemination. Blood 97 (2001) 2121-2129
18. Zhang W., Zhang X., Fan X., Li D., and Qiao Z. Effect of ICAM-1 and LFA-1 in hyperleukocytic acute myeloid leukaemia. Clin Lab Haematol 28 (2006) 177-182
19. Hug V., Keating M., McCredie K., Hester J., Bodey J.P., and Freireich E.J. Clinical course and response to treatment of patients with acute myelogenous leukemia presenting with a high leukocyte count. Cancer 52 (1983) 773-779
20. Cuttner J., Holland J.F., Norton L., Ambinder E., Button G., and Meyer R.J. Therapeutic leukapheresis for hyperleukocytosis in acute myelocytic leukaemia. Med Pediatr Oncol 11 (1983) 76-78
21. Lester T.J., Johnson J.W., and Cuttner J. Pulmonary leukostasis as the single worst prognostic factor in patients with acute myelocytic leukaemia and hyperleukocytosis. Am J Med 79 (1985) 43-48
22. Berg J., Vincent P.C., and Gunz F.W. Extreme leukocytosis and prognosis of newly diagnosed patients with acute non-lymphocytic leukaemia. Med J Aust 1 (1979) 480-482
23. Grund F.M., Armitage J.O., and Burns P. Hydroxyurea in the prevention of the effects of leukostasis in acute leukemia. Arch Intern Med 137 (1977) 1246-1247
24. Porcu P., Cripe L.D., Ng E.W., Bhatia S., Danielson C.M., Orazi A., et al. Hyperleukocytic leukemias and leukostasis: a review of pathophysiology, clinical presentation and management. Leuk Lymphoma 39 (2000) 1-18
25. Giles F.J., Shen Y., Kantarjian H.M., Korbling M.J., O'Brien S., Anderlini P., et al. Leukapheresis reduces early mortality in patients with acute myeloid leukaemia with high white cell counts but does not improve long-term survival. Leuk Lymphoma 42 (2001) 67-73
26. Ventura G.J., Hester J.P., Smith T.L., and Keating M.J. Acute myeloblastic leukaemia with hyperleukocytosis: risk factors for early mortality in induction. Am J Hematol 27 (1988) 34-37
27. Thiébaut A., Thomas X., Belhabri A., Anglaret B., and Archimbaud E. Impact of pre-induction therapy leukapheresis on treatment outcome in adult acute myelogenous leukaemia presenting with hyperleukocytosis. Ann Hematol 79 (2000) 501-506
28. Porcu P., Danielson C.F., Orazi A., Heerema N.A., Gabig T.G., and McCarthy L.J. Therapeutic leukapheresis in hyperleukocytic leukemias: lack of correlation between degree of cytoreduction and early mortality rate. Br J Haematol 98 (1997) 433-436
29. Swirsky D.M., de Bastos M., Parish S.E., Rees J.K., and Hayhoe F.G. Features affecting outcome during remission induction of acute myeloid leukaemia in 619 adult patients. Br J Haematol 64 (1986) 435-453
30. Löwenberg B., Suciu S., Archimbaud E., Ossenkoppele G., Verhoef G.E., Vellenga E., et al. Use of recombinant Granulocyte-Macrophage Colony-Stimulating Factor during and after remission induction chemotherapy in patients aged 61 years and older with acute myeloid leukaemia (AML): final report of AML-11, a Phase III randomized study of the Leukemia Cooperative Group of European Organization for the Research and Treatment of Cancer (EORTC-LCG) and the Dutch Belgian Hemato-Oncology Cooperative Group (HOVON). Blood 90 (1997) 2952-2961